Our Vision
To substantially and equitably mitigate harms from substance use regionally and nationally.


Medications for Opioid Use Disorder (MOUD)

Yes we have effective medications: Read about buprenorphine, methadone and naltrexone.

Substance Use Navigator Team

Our substance use navigators are the special people that make this all work.

Success Stories

Addiction is a family disease. While the Smith family came to Philadelphia to be at their father’s bedside during his final days, securing their brother’s medication for opioid use disorder became a barrier. Our CRS team mended this gap of need; offering much needed peace to a family’s already trying time.


What is an “X Waiver” and who needs one?

This legal waiver is no longer required for a clinician to prescribe the lifesaving medication buprenorphine. A major shift in policy allows any DEA registered provider to prescribe the drug going forward.

Receive CPE Credit for Attending our Virtual Webinar

Low-barrier care is essential to support our patients. CPE credit available for pharmacists/pharmacy students


Narcan is a highly effective antidote to opioid overdose: Learn how to use it!


A new clinical trial in the Penn Presbyterian ED to help start patients on the medication buprenorphine.

Research in the News

Read about our program in our “playbook” for other EDs to start an ED buprenorphine program


‘I didn’t have it in my bag before’: Incoming Penn students say carrying Narcan is shaping their outlook on medicine

August 2023

FDA Approves First Over-the-Counter Naloxone Nasal Spray

March 2023
FDA News Release

‘What we need’: Families gets life-saving CHOP training as violence continues across Philly

February 2023

Implementation of an ED Buprenorphine Program

In 3 urban academic emergency departments (EDs), a onetime incentive for X-waiver training was offered.

Success Rates

Overall, 89% of eligible emergency physicians completed the X-waiver training during the 6-week incentive period.
Buprenorphine prescribing rates increased to 15% (from <1%) during the first 4 months of the program.
This study shows how enthusiastically emergency physicians embraced the opportunity to obtain this certification, which speaks to the shifting national conversation surrounding opioid use disorder," said Sean Foster, MD. "This also gives a 'playbook' to any leaders and administrators who may be looking for ways to get their group trained."
After the incentive, buprenorphine prescribing per OUD encounter increased from 0.5% to 16%.
Data comes from Providing Incentive for Emergency Physician X-Waiver Training: An Evaluation of Program Success and Postintervention Buprenorphine Prescribing https://www.annemergmed.com/article/S0196-0644(20)30140-2/pdf